LEXICON PHARMACEUTICALS, INC. Results from Clinical Study of Sotagliflozin in Type 1 Diabetes Patients
The Woodlands, Texas, May 12, 2015 - Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that the manuscript entitled "Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes" has been selected to present at the 75th Scientific Sessions of the American Diabetes Association (ADA) in Boston on June 6, 2015, at 9:00 a.m. Eastern Time. The presentation will be part of the 4th Annual Diabetes Care Symposium and will be featured in a special July issue of Diabetes Care. This high-level symposium represents a competition of manuscripts submitted to the journal and dedicated to the theme of "Novel Clinical Interventions in Therapy That Impact the Management of Diabetes." The manuscript was selected from over 150 manuscripts that were submitted for the competition and will be available online on June 6, 2015, at care.diabetesjournals.org.
About Lexicon
Lexicon is a biopharmaceutical company focused on developing breakthrough treatments for human disease. Lexicon has clinical-stage drug programs for diabetes, carcinoid syndrome, and other indications, all of which were discovered by Lexicon's research team. Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets. For additional information about Lexicon and its programs, please visit www.lexpharma.com.
Safe Harbor Statement
This press release contains "forward-looking statements," including statements relating to Lexicon's clinical development of sotagliflozin (LX4211), including characterizations of the results of and projected timing of clinical trials and the potential therapeutic and commercial potential of sotagliflozin. In addition, this press release also contains forward-looking statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to meet its capital requirements, successfully conduct clinical development of sotagliflozin and preclinical and clinical development of its other potential drug candidates, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2014, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.
|
distributed by
|
